Navigation Links
Mens Sexual Prowess Not Affected by Prostate Cancer Drug

Men worried about taking finasteride, a drug proven effective in preventing prostate cancer, just because it might effect their performance in the bedroom, can now put their fears to rest, thanks to a new study.

The study, by researchers from the Southwest Oncology Group, found that though the drug does cause a drop in sexual function, the effects diminish over the course of time.

As a part of their study, the researchers surveyed more than 17,000 men 55 and older for seven years, and found that though men given finasteride reported on average more dysfunction than did men given a placebo, the small effect diminished over the seven years.

The study was led by Carol Moinpour, Ph.D., of the Fred Hutchison Cancer Research Center in Seattle.

The study grew out of the Prostate Cancer Prevention Trial, a large double-blind National Cancer Institute-funded study which found that finasteride, a drug which curbs the proliferation of prostate gland cells, is effective at preventing prostate cancer in men age 55 and older.

The 2003 results of that trial, conducted by the Southwest Oncology Group in more than 18,000 men, showed that finasteride could reduce a mans chances of getting prostate cancer by almost 25 percent.

In earlier studies, some men taking finasteride reported decreased libido, impotence and other signs of diminished sexual function. But researchers conducting the new study reported that the previous studies were studies were short-term and didnt try to assess the effects of age and other health factors, as well as individual variation.

The study authors used two surveys, a widely used Sexual Problems Scale and another questionnaire which they created, the Sexual Activity Scale. They also gathered other data to take into account other health factors that affect sexual function, such as age, medical conditions and smoking status. They surveyed the subjects three times in the first year and then annually for seven years.

Was this average decrease (in sexual function) an important difference? We concluded it was not, Moinpour said, adding that there were much larger differences due simply to individual variation among men in the trial.

The study suggests that finasteride will cause little or no sexual dysfunction for most men who decide to take it, conclude the authors.


'"/>




Related medicine news :

1. Sexual abuse affect health for a lifetime
2. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
3. Incidence Of Sexually Transmitted Diseases Among Gay Men On The Rise
4. Testosterone Patches Found To Increase Sexual Desire In Menopausal Women
5. Condom Vending Machines Increasing Sexual Assaults On Women
6. Sexually Abused Girls Develop Eating Disorders
7. Gynaecologist Faces Stiff Prison Sentence On Counts Of Sexual Abuse
8. New Sexual Misconduct Rule Against Doctors In The US
9. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
10. Youth Becoming Sexually Active At A Younger Age
11. Epilepsy Medicine May Result In Sexual Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: